Juan Durán de la Colina

Dr. Juan Durán de la Colina


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2011 in Eye
Verified
Journal Article
Closed access
AAA Acera
A Acera
Elena VecinoElena Vecino
Elena Vecino
IRI Rodríguez-Agirretxe
I Rodríguez-Agirretxe
KAKerman Aloria
Kerman Aloria
JAJesus M. Arizmendi
Jesus M. Arizmendi
JCJuan Durán de la Colina
Juan Durán de la Colina

Verified
Journal Article
Open access
PDF file
CBCarlota Suárez Barrio
Carlota Suárez Barrio
JEJaime Etxebarria
Jaime Etxebarria
RHRAQUEL HERNÁEZ
RAQUEL HERNÁEZ
MVMarina del Val-Alonso
Marina del Val-Alonso
MRMaddalen Rodriguez-Astigarraga
Maddalen Rodriguez-Astigarraga
Noelia AndolloNoelia Andollo
Noelia Andollo
The aim of this study is to assess if an adhesive biopolymer, sodium hyaluronate (NaHA), has synergistic effects with s-PRGF (a serum derived from plasma rich in growth factors and a blood derivative that has already shown efficacy in corneal epithelial wound healing), to reduce time of healing or posology. In vitro proliferation and migration studies, both in human corneal epithelial (HCE) cells and in rabbit primary corneal epithelial (RPCE) cultures, were carried out. In addition, we performed studies of corneal wound healing in vivo in rabbits treated with s-PRGF, NaHA, or the combination of both. We performed immunohistochemistry techniques (CK3, CK15, Ki67, ß4 integrin, ZO-1, α-SMA) in rabbit corneas 7 and 30 days after a surgically induced epithelial defect. In vitro results show that the combination of NaHA and s-PRGF offers the worst proliferation rates in both HCE and RPCE cells. Addition of NaHA to s-PRGF diminishes the re-epithelializing capability of s-PRGF. In vivo, all treatments, given twice a day, showed equivalent efficacy in corneal epithelial healing. We conclude that the combined use of s-PRGF and HaNA as an adhesive biopolymer does not improve the efficacy of s-PRGF alone in the wound healing of corneal epithelial defects.

Verified
Journal Article
Open access
PDF file
PMPablo Andrés Morales
Pablo Andrés Morales
JCJuan Durán de la Colina
Juan Durán de la Colina
Keratoconus is a progressive corneal disorder that causes thinning and irregular astigmatism, often leading to significant visual impairment. In the advanced stages, surgical interventions are necessary to restore corneal shape, improve vision, and enhance contact lens tolerance. Intracorneal ring segments (ICRSs) have emerged as a well-established, minimally invasive option that not only improves vision but also has the potential to delay or prevent the need for corneal transplantation in advanced cases. Recent advancements in the ICRS implantation techniques, patient selection, and femtosecond laser technology have significantly improved the precision and safety of these procedures, reducing complications. The ability to customize the ring parameters—such as thickness, arc length, and positioning—enables a more individualized approach, particularly for patients with irregular astigmatism. Artificial intelligence (AI) is also emerging as a promising tool for optimizing ICRS planning and improving patient outcomes. Although still in the early stages, AI algorithms may refine the treatment strategies by analyzing large datasets, improving the patient selection, and predicting long-term outcomes. Corneal Allogenic Intrastromal Ring Segments (CAIRSs) offer a novel alternative to synthetic ICRSs, with advantages like improved biocompatibility and reduced extrusion risk. However, CAIRSs remain an evolving technique that requires further refinement and long-term evaluation to determine the tissue integration, the durability of the refractive outcomes, and the potential for late-onset complications. In conclusion, ICRSs continue to be a safe and effective option for managing advanced keratoconus. Ongoing refinement of the surgical approaches—combined with advancements such as femtosecond laser technology and the integration of AI—will ensure that both ICRSs and CAIRSs remain key components in the therapeutic arsenal for keratoconus, offering sustained visual improvements and the potential to delay or avoid corneal transplantation.

1 May 2003 in Archivos de la Sociedad Española de Oftalmología
Verified
Journal Article
Open access
AAA Arntz
A Arntz
MAM Arango
M Arango
JCJuan Durán de la Colina
Juan Durán de la Colina

1 December 2003 in Archivos de la Sociedad Española de Oftalmología
Verified
Journal Article
Open access
AAA Arntz
A Arntz
JCJuan Durán de la Colina
Juan Durán de la Colina
JPJi Pijoán
Ji Pijoán